Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 143

1.

A bone marrow toxicity model for ²²³Ra alpha-emitter radiopharmaceutical therapy.

Hobbs RF, Song H, Watchman CJ, Bolch WE, Aksnes AK, Ramdahl T, Flux GD, Sgouros G.

Phys Med Biol. 2012 May 21;57(10):3207-22. doi: 10.1088/0031-9155/57/10/3207. Epub 2012 May 1.

2.

Monte Carlo simulation of age-dependent radiation dose from alpha- and beta-emitting radionuclides to critical trabecular bone and bone marrow targets.

Dant JT, Richardson RB, Nie LH.

Phys Med Biol. 2013 May 21;58(10):3301-19. doi: 10.1088/0031-9155/58/10/3301. Epub 2013 Apr 25.

PMID:
23615276
3.

Redefining relative biological effectiveness in the context of the EQDX formalism: implications for alpha-particle emitter therapy.

Hobbs RF, Howell RW, Song H, Baechler S, Sgouros G.

Radiat Res. 2014 Jan;181(1):90-8. doi: 10.1667/RR13483.1.

4.

Absorbed fractions for alpha-particles in tissues of trabecular bone: considerations of marrow cellularity within the ICRP reference male.

Watchman CJ, Jokisch DW, Patton PW, Rajon DA, Sgouros G, Bolch WE.

J Nucl Med. 2005 Jul;46(7):1171-85.

5.

Dosimetry of bone metastases in targeted radionuclide therapy with alpha-emitting (223)Ra-dichloride.

Pacilio M, Ventroni G, De Vincentis G, Cassano B, Pellegrini R, Di Castro E, Frantellizzi V, Follacchio GA, Garkavaya T, Lorenzon L, Ialongo P, Pani R, Mango L.

Eur J Nucl Med Mol Imaging. 2016 Jan;43(1):21-33. doi: 10.1007/s00259-015-3150-2. Epub 2015 Aug 13.

PMID:
26266887
6.

The dosimetry of bone incorporating alpha-emitting radionuclides.

Montelius A, Burlin TE.

Br J Radiol. 1984 Jul;57(679):609-16.

PMID:
6733407
7.

Targeting of osseous sites with alpha-emitting 223Ra: comparison with the beta-emitter 89Sr in mice.

Henriksen G, Fisher DR, Roeske JC, Bruland ØS, Larsen RH.

J Nucl Med. 2003 Feb;44(2):252-9.

8.

A model of cellular dosimetry for macroscopic tumors in radiopharmaceutical therapy.

Hobbs RF, Baechler S, Fu DX, Esaias C, Pomper MG, Ambinder RF, Sgouros G.

Med Phys. 2011 Jun;38(6):2892-903.

9.

Marrow-sparing effects of 117mSn(4+)diethylenetriaminepentaacetic acid for radionuclide therapy of bone cancer.

Bishayee A, Rao DV, Srivastava SC, Bouchet LG, Bolch WE, Howell RW.

J Nucl Med. 2000 Dec;41(12):2043-50.

11.

Dosimetry of 223Ra-chloride: dose to normal organs and tissues.

Lassmann M, Nosske D.

Eur J Nucl Med Mol Imaging. 2013 Jan;40(2):207-12. doi: 10.1007/s00259-012-2265-y. Epub 2012 Oct 11.

PMID:
23053328
12.

Myelotoxicity and RBE of 211At-conjugated monoclonal antibodies compared with 99mTc-conjugated monoclonal antibodies and 60Co irradiation in nude mice.

Elgqvist J, Bernhardt P, Hultborn R, Jensen H, Karlsson B, Lindegren S, Warnhammar E, Jacobsson L.

J Nucl Med. 2005 Mar;46(3):464-71.

13.

Considerations of marrow cellularity in 3-dimensional dosimetric models of the trabecular skeleton.

Bolch WE, Patton PW, Rajon DA, Shah AP, Jokisch DW, Inglis BA.

J Nucl Med. 2002 Jan;43(1):97-108.

14.
15.

A Phase 1, Open-Label Study of the Biodistribution, Pharmacokinetics, and Dosimetry of 223Ra-Dichloride in Patients with Hormone-Refractory Prostate Cancer and Skeletal Metastases.

Chittenden SJ, Hindorf C, Parker CC, Lewington VJ, Pratt BE, Johnson B, Flux GD.

J Nucl Med. 2015 Sep;56(9):1304-9. doi: 10.2967/jnumed.115.157123. Epub 2015 Jul 16.

16.

Quantitative comparisons of cancer induction in humans by internally deposited radionuclides and external radiation.

Harrison JD, Muirhead CR.

Int J Radiat Biol. 2003 Jan;79(1):1-13. Review.

PMID:
12556326
17.

A compartmental model of mouse thrombopoiesis and erythropoiesis to predict bone marrow toxicity after internal irradiation.

Sas N, Rousseau J, Nguyen F, Bellec E, Larrsson E, Becavin S, Hindorf C, Abadie J, Chouin N, Barbet J.

J Nucl Med. 2014 Aug;55(8):1355-60. doi: 10.2967/jnumed.113.133330. Epub 2014 Jun 16.

18.
19.

Marrow toxicity of 33P-versus 32P-orthophosphate: implications for therapy of bone pain and bone metastases.

Goddu SM, Bishayee A, Bouchet LG, Bolch WE, Rao DV, Howell RW.

J Nucl Med. 2000 May;41(5):941-51.

20.

Comparison of multiple bolus and continuous injections of 131I-labeled CC49 for therapy in a colon cancer xenograft model.

Buchsbaum DJ, Khazaeli MB, Mayo MS, Roberson PL.

Clin Cancer Res. 1999 Oct;5(10 Suppl):3153s-3159s.

PMID:
10541357

Supplemental Content

Support Center